Medical device provider Medrad and Massachusetts General Hospital (MGH) in Boston have entered into an agreement that will aid the hospital with its research in lung function using PET imaging.

Via the terms of the agreement, MGH will pilot a device that will process and inject N13 gas and dissolved in saline for research in both pre-clinical and clinical PET studies by way of Medrad’s controlled fluid delivery technology and programming interface capabilities.

According to the Warrendale, Pa.-based company, the technique will enable acquisition of spatially co-registered functional images of lung perfusion and ventilation in a single procedure.